Analyst Conference Summaries

Biotechnology Investor Aids

ImmunoGen
IMGN

conference date: May 10, 2021 @ 5:00 AM Pacific Time

ImmunoGen Price Run-Up Driven by Potential Trial Data [Feb. 6, 2018 at SA]

AML Therapies, Part 2: Agios and Immunogen [September 29, 2016 at Seeking Alpha]

ImmunoGen Oversold Despite Strong Pipeline [July 7, 2016 at Seeking Alpha]

2021
ImmunoGen
Q1 2021
     
May 10, 2021      
2020
ImmunoGen
Q1 2020
ImmunoGen
Q2 2020
ImmunoGen
Q3 2020
ImmunoGen
Q4 2020
May 1, 2020 July 31, 2020 Nov. 6, 2020 Feb. 12, 2021
2019
ImmunoGen
Q1 2019
ImmunoGen
Q2 2019
ImmunoGen
Q3 2019
ImmunoGen
Q4 2019
May 3, 2019 August 2, 2019 Nov. 1, 2019 Feb. 14, 2020
2018
ImmunoGen
Q4 2018
May 4, 2018
July 27, 2018
Nov. 2, 2018
Feb. 8, 2018
2017
May 5, 2017
July 28, 2017
Nov. 3, 2017
Feb. 9, 2018
2016
04/29/2016
08/04/2016
10/28/2016
02/17/2017

Immunogen (IMGN) is a clinical-stage biotechnology company specializing in ADC's (antibody-drug conjugates) for cancer and other diseases.

Immunogen web site

sold my last on Dec. 17, 2019

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 DRNA
 EPZM
 GILD
 GLYC
 ILMN
 INCY
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLRN
     

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2021 William P. Meyers